112 related articles for article (PubMed ID: 1452490)
1. Antibacterial profile of flurithromycin, a new macrolide.
Saverino D; Debbia EA; Pesce A; Lepore AM; Schito GC
J Antimicrob Chemother; 1992 Sep; 30(3):261-72. PubMed ID: 1452490
[TBL] [Abstract][Full Text] [Related]
2. Comparative antimicrobial activity of the new macrolide flurithromycin against respiratory pathogens.
Nord CE; Lindmark A; Persson I
Eur J Clin Microbiol Infect Dis; 1988 Feb; 7(1):71-3. PubMed ID: 3132384
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial activity of the new macrolide flurithromycin against Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus pyogenes, Branhamella catarrhalis and Staphylococcus aureus.
Nord CE; Lindmark A; Persson I
J Chemother; 1989 Jul; 1(4 Suppl):203-4. PubMed ID: 16312369
[No Abstract] [Full Text] [Related]
4. In vitro activity of flurithromycin, a novel macrolide antibiotic.
Gialdroni Grassi G; Alesina R; Bersani C; Ferrara A; Fietta A; Peona V
Chemioterapia; 1986 Jun; 5(3):177-84. PubMed ID: 3487389
[TBL] [Abstract][Full Text] [Related]
5. Multicenter surveillance of antimicrobial resistance of Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 14 oral antibiotics.
Hsueh PR; Huang WK; Shyr JM; Lau YJ; Liu YC; Luh KT
J Formos Med Assoc; 2004 Sep; 103(9):664-70. PubMed ID: 15361938
[TBL] [Abstract][Full Text] [Related]
6. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
Noviello S; Ianniello F; Leone S; Esposito S
J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
[TBL] [Abstract][Full Text] [Related]
7. Postantibiotic effect of roxithromycin, erythromycin, and clindamycin against selected gram-positive bacteria and Haemophilus influenzae.
Kuenzi B; Segessenmann C; Gerber AU
J Antimicrob Chemother; 1987 Nov; 20 Suppl B():39-46. PubMed ID: 3501426
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of A-56268 (TE-031), a new macrolide, compared with that of erythromycin and clindamycin against selected gram-positive and gram-negative organisms.
Benson CA; Segreti J; Beaudette FE; Hines DW; Goodman LJ; Kaplan RL; Trenholme GM
Antimicrob Agents Chemother; 1987 Feb; 31(2):328-30. PubMed ID: 2952063
[TBL] [Abstract][Full Text] [Related]
9. Bactericidal kinetics and postantibiotic effect of sparfloxacin against selected species of respiratory pathogens.
Speciale A; Blandino G; Nicolosi VM; Siracusa V; Caccamo F
J Chemother; 1995 Dec; 7(6):530-4. PubMed ID: 8667038
[TBL] [Abstract][Full Text] [Related]
10. Parameters characterizing the in vitro activity of cefixime, a new oral broad spectrum cephalosporin, against respiratory and urinary pathogens.
Debbia EA; Marchese A; Pesce A; Saverino D; Schito GC
J Chemother; 1992 Jun; 4(3):131-44. PubMed ID: 1517806
[TBL] [Abstract][Full Text] [Related]
11. Gepotidacin (GSK2140944)
Flamm RK; Farrell DJ; Rhomberg PR; Scangarella-Oman NE; Sader HS
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483959
[TBL] [Abstract][Full Text] [Related]
12. Comparative in-vitro activity of azithromycin and erythromycin against Gram-positive cocci, Haemophilus influenzae and anaerobes.
Maskell JP; Sefton AM; Williams JD
J Antimicrob Chemother; 1990 Jan; 25 Suppl A():19-24. PubMed ID: 2154433
[TBL] [Abstract][Full Text] [Related]
13. Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential.
Peters DH; Clissold SP
Drugs; 1992 Jul; 44(1):117-64. PubMed ID: 1379907
[TBL] [Abstract][Full Text] [Related]
14. Antibacterial activity and post-antibiotic effect of flurithromycin compared with other macrolides and penicillins against periodontal pathogens.
Lo Bue AM; Blandino G; Milazzo I; Pasquantonio G; Speciale A; Nicoletti G
J Chemother; 2001 Jun; 13(3):255-9. PubMed ID: 11450882
[TBL] [Abstract][Full Text] [Related]
15. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1994)].
Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kobayashi K; Satou K; Matsumiya H; Saito A; Terai T; Tanno Y; Nishioka K; Arakawa M; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Matsuda M; Tanimoto H; Nakata K; Nakamori Y; Kusano N
Jpn J Antibiot; 1996 May; 49(5):419-55. PubMed ID: 8752860
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of ertapenem against selected respiratory pathogens.
Marchese A; Gualco L; Schito AM; Debbia EA; Schito GC
J Antimicrob Chemother; 2004 Nov; 54(5):944-51. PubMed ID: 15472001
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
[TBL] [Abstract][Full Text] [Related]
18. Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae.
Walsh F; Carnegy F; Willcock J; Amyes S
J Antimicrob Chemother; 2004 May; 53(5):793-6. PubMed ID: 15056640
[TBL] [Abstract][Full Text] [Related]
19. In vitro brodimoprim activity on bacterial strains.
Benoit-Lemercier C; Bergogne-Bérézin E; Joly-Guillou ML
J Chemother; 1993 Dec; 5(6):435-43. PubMed ID: 8195835
[TBL] [Abstract][Full Text] [Related]
20. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1992)].
Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kobayashi K; Satou K; Matsumiya H; Saito A; Terai T; Tanno Y; Nishioka K; Arakawa M; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Tanimoto H; Nakata K; Nakamori Y; Nakatani T; Kusano N
Jpn J Antibiot; 1996 Jan; 49(1):34-70. PubMed ID: 8851305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
